Anti-FMDV VP1 Polyclonal Antibody from ProteoGenix; catalogue ARO-A22295; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Introducing our highly effective Anti-FMDV VP1 Polyclonal Antibody – the perfect solution for researchers and scientists working in the field of biotechnology. This powerful antibody is specifically designed to target and neutralize the Foot-and-Mouth Disease Virus (FMDV) VP1 protein, making it an essential tool for studying and combating this highly contagious viral disease.
The main biological function of our Anti-FMDV VP1 Polyclonal Antibody is to bind to and block the activity of the VP1 protein, which is crucial for the replication and spread of FMDV. By inhibiting the function of this protein, our antibody effectively prevents the virus from infecting and replicating in host cells.
This antibody has a wide range of applications in the biotech industry, including research, diagnostics, and vaccine development. It can be used in various techniques such as ELISA, western blotting, and immunohistochemistry to detect and quantify the presence of FMDV in samples. It can also be used in studies to understand the mechanisms of FMDV infection and to develop potential treatments and vaccines.
Our Anti-FMDV VP1 Polyclonal Antibody has been extensively tested and validated in various experimental settings. In one study, it was used to successfully neutralize FMDV in infected cells, demonstrating its ability to block viral replication. In another study, it was used to detect and quantify FMDV in clinical samples with high sensitivity and specificity. These results highlight the reliability and effectiveness of our antibody in experimental use cases.
In summary, our Anti-FMDV VP1 Polyclonal Antibody is a highly specific and potent tool for studying and combating FMDV. Its ability to bind to and neutralize the VP1 protein makes it an invaluable resource for researchers and scientists in the biotech industry. With its wide range of applications and proven effectiveness in experimental studies, it is a must-have for any lab working on FMDV research. Order now and take a step towards understanding and fighting this devastating viral disease.
ProteoGenix catalogue number ARO-A22295. For research use only.
Target: capsid protein, partial; capsid protein, partial; Clonality: Polyclonal Antibody; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| capsid protein, partial; capsid protein, partial |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
